838 related articles for article (PubMed ID: 30324406)
21. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
22. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
[TBL] [Abstract][Full Text] [Related]
23. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
24. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
25. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
26. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
27. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
[TBL] [Abstract][Full Text] [Related]
28. Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study.
Dalén J; Puenpatom A; Luttropp K; Svedbom A; Black CM
Adv Ther; 2022 Jan; 39(1):244-255. PubMed ID: 34480294
[TBL] [Abstract][Full Text] [Related]
29. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
[TBL] [Abstract][Full Text] [Related]
30. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study.
Dalén J; Chitkara A; Svedbom A; Olofsson T; Puenpatom A; Black CM; Qureshi ZP
Adv Ther; 2022 Jun; 39(6):2468-2486. PubMed ID: 34751912
[TBL] [Abstract][Full Text] [Related]
31. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
[TBL] [Abstract][Full Text] [Related]
32. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
[TBL] [Abstract][Full Text] [Related]
33. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
34. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
37. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Chovel-Sella A; Karplus R; Sella T; Amital H
Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
[TBL] [Abstract][Full Text] [Related]
39. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
[TBL] [Abstract][Full Text] [Related]
40. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
